Senior Research Awards
The Fellowships are of three years duration and enable practitioners to devote up to half of their working time to research. Fellowships have been awarded to:
Clinical Professor John Burnett
John Burnett is a Consultant Medical Biochemist in the Department of Clinical Biochemistry, PathWest Laboratory Medicine WA at Royal Perth Hospital and Clinical Professor in the School of Medicine & Pharmacology at The University of Western Australia.
His project is “Understanding naturally low cholesterol states – the development of new strategies to help people with high cholesterol and cardiovascular disease”.
Associate Professor David Nolan
David Nolan is a Consultant Physician in the Royal Perth Hospital Immunology Department, with clinical duties involving a range of systemic autoimmune and immune deficiency syndromes including a large HIV cohort.
His project is “The role of genetic factors in the risk and progression of Multiple Sclerosis; the link between HIV infection and age associated conditions such as cardiovascular disease”.
Clinical Professor Steven Webb
Steven Webb is a Senior Staff Specialist in Intensive Care Medicine at Royal Perth Hospital, a Clinical Professor in the School of Medicine and Pharmacology and the School of Population Health at The University of Western Australia, and a Clinical Professor in the Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University.
His project is “Treatment protocols for patients with critical illness in an ICU”.
Winthrop Professor Fiona Wood
Fiona Wood is a Plastic & Reconstructive Surgeon specialising in the field of burn care, trauma and scar reconstruction. She is the Director of the WA Burns Service of Western Australia and a Consultant Plastic Surgeon at Princess Margaret Hospital and Royal Perth Hospital.
Her project is “How nerves grow back into skin following burn injury”.
The Postdoctoral Fellowships are of three years duration, enabling scientists to complete a research project within a department at Royal Perth Hospital. Fellowships have been awarded to:
Dr Keith Giles
Keith Giles completed his initial undergraduate BSc at Curtin University in 1995 and subsequently was awarded his PhD in 2004. He then took up a postdoctoral position within the Western Australian Institute for Medical Research and has been awarded a series of competitive grants and awards.
Keith’s project is “A new approach to treating melanoma – use of a molecule (a microRNA) to control the growth and spread of melanoma”.
Research Asst. Professor Jon Pfaff
Jon Pfaff is a Specialist Clinical Psychologist. He graduated cum laude from Rollins College (USA) with honours in psychology, before completing his postgraduate clinical training (MSc, Clinical Psychology) at Memorial University of Newfoundland (Canada) and his postgraduate research training at The University of Western Australia (PhD).
Jon’s project is “Changing behaviour to alleviate depression in older people – improved evidence based treatment of depression in older adults”.
Research Asst. Professor Natalie Ward
Natalie Ward completed her BSc at the Australian National University in 1999 and her PhD at The University of Western Australia in 2004. Her most recent appointment was as a National Heart Foundation Postdoctoral Fellow for 2010 to 2012.
Natalie’s project is “The effect of fatty acid metabolites on stroke outcomes”.
Dr Andrew Woo
Andrew Woo is currently a Research Fellow in the Department of Haematology/Oncology at the Children’s Hospital Boston/Harvard Medical School. He has a PhD in Biochemistry, having graduated with Honours in Biochemistry from The University of Western Australia in 1997.
Andrew’s project is “The role of microRNAs in reducing the growth and invasion of prostate cancer”.
Major Research Grant
In late 2011 the Committee of Management approved the largest grant ever given by the Foundation. The grant, totalling $656,268 over three years, was awarded to Clinical Professor Richard Herrmann for a project entitled “A randomised trial of mesenchymal stromal cell therapy to treat newly diagnosed acute graft versus host disease”.